Summit Therapeutics (SMMT) Return on Capital Employed (2020 - 2024)
Summit Therapeutics (SMMT) posted quarterly Return on Capital Employed of 52.87% for Q4 2024, up 26748.0% year-on-year from N/an in Q1 2024, and up 2.29% on a QoQ basis from 54.11% in Q3 2024.
Summit Therapeutics (SMMT) Return on Capital Employed (2020 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has reported Return on Capital Employed for 5 consecutive years, with 52.87% the latest figure, recorded in Q4 2024.
- Quarterly Return on Capital Employed rose 26748.0% year-over-year to 52.87% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 52.87% (up 26748.0% YoY) and the FY2024 annual result came in at 81.43%, up 6613.0% from the prior year.
- Return on Capital Employed rose to 52.87% in Q4 2024 per SMMT's latest filing, from 54.11% in the prior quarter.
- Over the last five years, Return on Capital Employed for SMMT reached as high as 19.43% in Q4 2022 and fell as low as 519.99% in Q3 2023.
- A 5-year average of 132.71% and a median of 90.34% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 44848 bps — and 2024, when it soared 46589 bps.
- Year by year, Return on Capital Employed stood at 108.08% in 2020, then rose by 16 bps to 90.34% in 2021, then jumped by 78 bps to 19.43% in 2022, then plunged by 1549 bps to 320.35% in 2023, then surged by 83 bps to 52.87% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 52.87%, 54.11%, and 133.2% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -52.87% |
| Sep 30, 2024 | -54.11% |
| Jun 30, 2024 | -133.20% |
| Mar 31, 2024 | -69.03% |
| Dec 31, 2023 | -320.35% |
| Sep 30, 2023 | -519.99% |
| Jun 30, 2023 | -252.00% |
| Mar 31, 2023 | -132.80% |
| Dec 31, 2022 | -19.43% |
| Sep 30, 2022 | -71.51% |
| Jun 30, 2022 | -88.41% |
| Mar 31, 2022 | -99.16% |
| Dec 31, 2021 | -90.34% |
| Sep 30, 2021 | -62.72% |
| Jun 30, 2021 | -57.02% |
| Mar 31, 2021 | -125.07% |
| Dec 31, 2020 | -108.08% |